Re: VERY KEEN on Nasdaq listing....
|
2
|
Resverlogix Corp.
|
Sep 10, 2015 11:10AM
|
RVX Blog: ESC CONGRESS 2016 EPIGENETICS SYMPOSIUM: KOL VIDEO PRESENTATIONS
|
2
|
Resverlogix Corp.
|
Oct 05, 2016 04:11PM
|
Re: Lilly to Discontinue Development of Evacetrapib
|
2
|
Resverlogix Corp.
|
Nov 13, 2015 04:06PM
|
Re: Resverlogix BIO CEO & Investor Conference 2017 Slides
|
2
|
Resverlogix Corp.
|
Feb 14, 2017 02:08PM
|
Resverlogix Announces Proposed Offering of Units
|
2
|
Resverlogix Corp.
|
May 14, 2019 06:13PM
|
Re: An ESC video from youtube that mentions Apabetalone, posted July 10 2019
|
2
|
Resverlogix Corp.
|
Sep 09, 2019 08:19PM
|
Re: Do we know what RRR % we got for 5 point MACE
|
2
|
Resverlogix Corp.
|
Nov 16, 2019 04:32PM
|
Re: News !!!
|
2
|
Resverlogix Corp.
|
Feb 26, 2018 08:30PM
|
Resverlogix Closes US$30 Million Loan
|
2
|
Resverlogix Corp.
|
May 07, 2018 07:10AM
|
Resverlogix Provides Unrestricted Educational Grant for Epigenetic Symposium at International Renal Congress
|
2
|
Resverlogix Corp.
|
May 24, 2018 08:33AM
|
Rising Tide Equity, LLC Publishes Initial Equity Report on biOasis Technologies
|
2
|
BIOASIS TECHNOLOGIES INC
|
Oct 25, 2016 10:51AM
|
Re: When in Rome.......
|
2
|
Resverlogix Corp.
|
Aug 27, 2016 05:19PM
|
Re: ZEN003694 Trial Now Listed on ClinicalTrials.gov
|
2
|
Zenith Epigenetics
|
Mar 13, 2016 09:46PM
|
Voyager, AAVs and Gene Targeted Therapies
|
2
|
BIOASIS TECHNOLOGIES INC
|
Feb 24, 2019 03:48PM
|
Re: State of Emergency
|
2
|
Resverlogix Corp.
|
Jul 23, 2016 10:35AM
|
Resverlogix Announces Annual and Special Meeting of Shareholders
|
2
|
Resverlogix Corp.
|
Aug 22, 2019 07:12PM
|
Re: American Society of Nephrology Kidney Week
|
2
|
Resverlogix Corp.
|
Nov 03, 2017 08:16AM
|
Re: ...is anybody out there at the AGM...?
|
2
|
Resverlogix Corp.
|
Oct 01, 2015 01:22PM
|
Breaking Down Barriers: BiOasis Technologies Promises Breakthrough Brain Drug Delivery
|
2
|
BIOASIS TECHNOLOGIES INC
|
Jun 19, 2018 02:08PM
|
Re: ...webcast is up> LINK...
|
2
|
Resverlogix Corp.
|
Mar 11, 2019 01:05PM
|